{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:23:35Z","timestamp":1761845015506,"version":"3.37.3"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T00:00:00Z","timestamp":1554854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA091078"],"award-info":[{"award-number":["T32CA091078"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA183926"],"award-info":[{"award-number":["T32CA183926"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0214469","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T17:52:41Z","timestamp":1554918761000},"page":"e0214469","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells"],"prefix":"10.1371","volume":"14","author":[{"given":"Laura L.","family":"Stafman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raoud","family":"Marayati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie M.","family":"Aye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry E.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Mroczek-Musulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4613-0527","authenticated-orcid":true,"given":"Elizabeth A.","family":"Beierle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,4,10]]},"reference":[{"key":"ref1","first-page":"560","article-title":"Epidemiology of primary hepatic malignancies in U.S. children","volume":"38","author":"A. Darbari","year":"2003"},{"key":"ref2","first-page":"150","article-title":"Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: new trends and future opportunities","volume":"153","author":"R. J. Cruz","year":"2013"},{"key":"ref3","first-page":"883","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"V. Brinkmann","year":"2010"},{"key":"ref4","first-page":"23106","article-title":"The emerging role of FTY720 (Fingolimod) in cancer treatment","volume":"7","author":"C. White","year":"2016"},{"key":"ref5","first-page":"375","article-title":"Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway","volume":"30","author":"K. T. Ng","year":"2007"},{"key":"ref6","first-page":"1430","article-title":"Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma","volume":"4","author":"J. W. Ho","year":"2005"},{"key":"ref7","first-page":"2397","article-title":"FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation","volume":"25","author":"T. K. Lee","year":"2004"},{"key":"ref8","first-page":"9","article-title":"Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer","volume":"335","author":"P. Seshacharyulu","year":"2013"},{"key":"ref9","first-page":"19011","article-title":"Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner","volume":"104","author":"S. Andrabi","year":"2007"},{"key":"ref10","first-page":"41377","article-title":"Protein phosphatase 2A, a negative regulator of the ERK signaling pathway, is activated by tyrosine phosphorylation of putative HLA class II-associated protein I (PHAPI)\/pp32 in response to the antiproliferative lectin, jacalin","volume":"279","author":"L. G. Yu","year":"2004"},{"key":"ref11","first-page":"2832","article-title":"Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation","volume":"26","author":"H. K. Arnold","year":"2006"},{"key":"ref12","first-page":"22649","article-title":"PR55 alpha, a regulatory subunit of PP2A, specifically regulates PP2A-mediated beta-catenin dephosphorylation","volume":"284","author":"W. Zhang","year":"2009"},{"key":"ref13","first-page":"7","article-title":"Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations","volume":"21","author":"M. C. Curia","year":"2008"},{"key":"ref14","first-page":"26241","article-title":"Coordinated activities of multiple Myc-dependent and Myc-independent biosynthetic pathways in hepatoblastoma","volume":"291","author":"H. Wang","year":"2016"},{"key":"ref15","first-page":"4538","article-title":"Activation of phosphatidylinositol-3&apos;-kinase\/AKT signaling is essential in hepatoblastoma survival","volume":"15","author":"W. Hartmann","year":"2009"},{"key":"ref16","first-page":"26","article-title":"Involvement of PI3K\/Akt, ERK and p38 signaling pathways in emodin-mediated extrinsic and intrinsic human hepatoblastoma cell apoptosis","volume":"92","author":"Y. Cui","year":"2016"},{"key":"ref17","first-page":"5438","article-title":"Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers","volume":"70","author":"K. G. Roberts","year":"2010"},{"key":"ref18","first-page":"2408","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"P. Neviani","year":"2007"},{"key":"ref19","first-page":"938","article-title":"PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential","volume":"13","author":"I. Crist\u00f3bal","year":"2014"},{"key":"ref20","first-page":"138","article-title":"Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models","volume":"19","author":"R. Rosa","year":"2013"},{"key":"ref21","first-page":"78","article-title":"Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia","volume":"6","author":"E. Arriazu","year":"2016"},{"key":"ref22","first-page":"955","article-title":"Current chemotherapeutic approaches for hepatoblastoma","volume":"18","author":"K. Watanabe","year":"2013"},{"key":"ref23","first-page":"440","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"T. C. Chou","year":"2010"},{"key":"ref24","first-page":"2571","article-title":"FTY720 for cancer therapy (Review)","volume":"30","author":"L. Zhang","year":"2013"},{"key":"ref25","first-page":"900","article-title":"Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite","volume":"74","author":"C. R. Strader","year":"2011"},{"key":"ref26","first-page":"11","article-title":"Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus","volume":"3","author":"K. Chiba","year":"2006"},{"key":"ref27","first-page":"2329","article-title":"The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod","volume":"19","author":"S. N. Patmanathan","year":"2015"},{"key":"ref28","first-page":"1915","article-title":"Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity","volume":"28","author":"R. Pippa","year":"2014"},{"key":"ref29","first-page":"4299","article-title":"PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects","volume":"6","author":"R. Rinc\u00f3n","year":"2015"},{"key":"ref30","first-page":"1300","article-title":"PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential","volume":"233","author":"B. K. Velmurugan","year":"2018"},{"key":"ref31","first-page":"3276","article-title":"Activation of the tumor suppressor PP2A emerges as a potential therapeutic strategy for treating prostate cancer","volume":"13","author":"I. Crist\u00f3bal","year":"2015"},{"key":"ref32","first-page":"5901","article-title":"Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers. identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas","volume":"23","author":"S. Yamada","year":"2004"},{"key":"ref33","first-page":"1734","article-title":"<italic>Mol Cell Biol<\/italic>","volume":"36","author":"I. Crist\u00f3bal","year":"2016"},{"key":"ref34","first-page":"168","article-title":"MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting \u03b2-catenin and Wnt signaling","volume":"1","author":"E. Indersie","year":"2017"},{"key":"ref35","first-page":"22","article-title":"Hepatoblastoma: a need for cell lines and tissue banks to develop targeted drug therapies","volume":"4","author":"R. R. Rikhi","year":"2016"},{"key":"ref36","first-page":"246","article-title":"FTY720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1","volume":"15","author":"Y. Xing","year":"2014"},{"key":"ref37","first-page":"1169","article-title":"FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression","volume":"34","author":"A. Ishitsuka","year":"2014"},{"key":"ref38","first-page":"2053","article-title":"Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy","volume":"42","author":"N. Zhang","year":"2013"},{"key":"ref39","first-page":"4811","article-title":"Inhibition of autophagy may suppress the development of hepatoblastoma","volume":"278","author":"Y. Chang","year":"2011"},{"key":"ref40","article-title":"Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors","volume":"18","author":"C. I. Chude","year":"2017"},{"key":"ref41","first-page":"164","article-title":"Evaluation of cell-proliferation antibodies reactive in paraffin sections","volume":"2","author":"L. Kelleher","year":"1994","journal-title":"Applied Immunohistochemistry"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0214469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T07:29:26Z","timestamp":1589009366000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0214469"}},"subtitle":[],"editor":[{"given":"Irina V.","family":"Lebedeva","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,4,10]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0214469","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,4,10]]}}}